We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

As frustrating as that is, there are things you can do to make sure that your doctor turns your symptoms into an accurate diagnosis. Here's what to know. The first step to getting an accurate ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, ...

The approval of Dupixent for bullous pemphigoid is expected to offer new hope to patients who have previously faced limited treatment options. With the potential to effectively manage symptoms and ...

EMERGING immunotherapies are transforming the treatment landscape for pemphigus and bullous pemphigoid, two distinct autoimmune blistering skin diseases marked by pathogenic autoantibodies and ...

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease Sanofi and Regeneron’s Dupixent ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administration (FDA) has approved ...

TARRYTOWN, NY, USA and PARIS, France I June 20, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the US Food and Drug Administration (FDA) has approved the drug for the ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). BP primarily affects elderly patients, and is ...